These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15002625)

  • 1. The medicine cabinet: what's in it, why, and can we change the contents?
    Croghan TW; Pittman PM
    Health Aff (Millwood); 2004; 23(1):23-33. PubMed ID: 15002625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicine and the pharmaceutical industry: what's right, what's wrong, and what's to come.
    Tan SY
    Singapore Med J; 1998 Mar; 39(3):91-5. PubMed ID: 9632964
    [No Abstract]   [Full Text] [Related]  

  • 3. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process.
    Ross ME; Nydick RL
    J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Portfolio analysis and R&D decision making.
    Evans R; Hinds S; Hammock D
    Nat Rev Drug Discov; 2009 Mar; 8(3):189-90. PubMed ID: 19182818
    [No Abstract]   [Full Text] [Related]  

  • 5. Designer drugs. What's best for patients isn't always what's best for profits.
    Sherrid P
    US News World Rep; 2001 Aug; 131(6):30-2. PubMed ID: 11508075
    [No Abstract]   [Full Text] [Related]  

  • 6. Negotiating innovative relationships with pharmaceutical companies: the pharmaceutical industry's perspective.
    Evans RT
    Am J Health Syst Pharm; 1996 Feb; 53(4 Suppl 1):S37-9. PubMed ID: 8673677
    [No Abstract]   [Full Text] [Related]  

  • 7. Rare essentials: drugs for rare diseases as essential medicines.
    Stolk P; Willemen MJ; Leufkens HG
    Bull World Health Organ; 2006 Sep; 84(9):745-51. PubMed ID: 17128345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 9. Incentives for biodefense countermeasure development.
    Matheny J; Mair M; Mulcahy A; Smith BT
    Biosecur Bioterror; 2007 Sep; 5(3):228-38. PubMed ID: 17903091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting U.S. manufacturers' decisions to produce vaccines.
    Coleman MS; Sangrujee N; Zhou F; Chu S
    Health Aff (Millwood); 2005; 24(3):635-42. PubMed ID: 15886154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. America's drug problem.
    Philpott S
    Hastings Cent Rep; 2012; 42(4):9-10. PubMed ID: 22777971
    [No Abstract]   [Full Text] [Related]  

  • 12. An unbalanced portfolio.
    Federsel HJ
    Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential Medicines in the United States--Why Access Is Diminishing.
    Alpern JD; Song J; Stauffer WM
    N Engl J Med; 2016 May; 374(20):1904-7. PubMed ID: 27192669
    [No Abstract]   [Full Text] [Related]  

  • 14. Sales and marketing's partnership role in class A MRP II (material requirements planning).
    Dougherty JR; Lerner W
    Hosp Mater Manage Q; 1994 Aug; 16(1):40-6. PubMed ID: 10135467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why are pharmaceutical companies gradually abandoning vaccines?
    Offit PA
    Health Aff (Millwood); 2005; 24(3):622-30. PubMed ID: 15886152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World pharmaceutical developments.
    Bale H
    World Hosp Health Serv; 2002; 38(2):1. PubMed ID: 12402745
    [No Abstract]   [Full Text] [Related]  

  • 17. Policing the European pharmaceutical market's priorities.
    Garattini S; Bertele' V
    Eur J Clin Pharmacol; 2000 Aug; 56(5):441-3. PubMed ID: 11009057
    [No Abstract]   [Full Text] [Related]  

  • 18. Why drug shortages occur.
    Drug Ther Bull; 2015 Mar; 53(3):33-6. PubMed ID: 25765598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.
    Hale VG; Woo K; Lipton HL
    Health Aff (Millwood); 2005; 24(4):1057-63. PubMed ID: 16012146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An information infrastructure for the pharmaceutical market.
    Reinhardt UE
    Health Aff (Millwood); 2004; 23(1):107-12. PubMed ID: 15002633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.